Myelination in the absence of UDP-galactose:ceramide galactosyl-transferase and fatty acid 2 -hydroxylase
- Marion Meixner†1,
- Julia Jungnickel†2,
- Claudia Grothe2,
- Volkmar Gieselmann1 and
- Matthias Eckhardt1Email author
© Meixner et al; licensee BioMed Central Ltd. 2011
Received: 31 October 2010
Accepted: 2 March 2011
Published: 2 March 2011
The sphingolipids galactosylceramide (GalCer) and sulfatide are major myelin components and are thought to play important roles in myelin function. The importance of GalCer and sulfatide has been validated using UDP-galactose:ceramide galactosyltransferase-deficient (Cgt-/-) mice, which are impaired in myelin maintenance. These mice, however, are still able to form compact myelin. Loss of GalCer and sulfatide in these mice is accompanied by up-regulation of 2-hydroxylated fatty acid containing (HFA)-glucosylceramide in myelin. This was interpreted as a partial compensation of the loss of HFA-GalCer, which may prevent a more severe myelin phenotype. In order to test this hypothesis, we have generated Cgt-/- mice with an additional deletion of the fatty acid 2-hydroxylase (Fa2h) gene.
Fa2h-/-/Cgt-/- double-deficient mice lack sulfatide, GalCer, and in addition HFA-GlcCer and sphingomyelin. Interestingly, compared to Cgt-/- mice the amount of GlcCer in CNS myelin was strongly reduced in Fa2h-/-/Cgt-/- mice by more than 80%. This was accompanied by a significant increase in sphingomyelin, which was the predominant sphingolipid in Fa2h-/-/Cgt-/- mice. Despite these significant changes in myelin sphingolipids, compact myelin was formed in Fa2h-/-/Cgt-/- mice, and g-ratios of myelinated axons in the spinal cord of 4-week-old Fa2h-/-/Cgt-/- mice did not differ significantly from that of Cgt-/- mice, and there was no obvious phenotypic difference between Fa2h-/-/Cgt-/- and Cgt-/- mice
These data show that compact myelin can be formed with non-hydroxylated sphingomyelin as the predominant sphingolipid and suggest that the presence of HFA-GlcCer and HFA-sphingomyelin in Cgt-/- mice does not functionally compensate the loss of HFA-GalCer.
In Cgt-/- mice, the loss of GalCer and sulfatide is accompanied by a significant upregulation of 2-hydroxylated fatty acid-containing (HFA) glucosylceramide (HFA-GlcCer) and HFA-sphingomyelin [3, 4]. Interestingly, there are no indications for presence of HFA-gangliosides or other higher glycosylated HFA-sphingolipids in the brain of Cgt-/- mice . The presence of HFA-GlcCer and HFA-sphingomyelin was interpreted as a compensatory upregulation, which may also (in part) functionally replace HFA-GalCer, enabling Cgt-/- mice to form compact myelin [3, 10].
HFA-sphingolipids in CNS and PNS myelin are synthesized from 2-hydroxylated fatty acids, formed by the fatty acid 2-hydroxylase (encoded by the Fa2h gene) [11–14]. Although loss of 2-hydroxylated sphingolipids in myelin does not affect initial myelin formation, it causes late onset (in mice older than 6 months) axon and myelin sheath degeneration . Fa2h-deficiency was identified as the cause of a new leukodystrophy with spastic paraparesis , and hereditary spastic paraplegia SPG35 , respectively.
In order to test the hypothesis that the presence of HFA-GlcCer and HFA-sphingomyelin in Cgt-/- mice is a functional important compensatory upregulation, preventing a more severe phenotype, we generated Cgt-/- mice with an additional deficiency in the Fa2h gene. Our analysis shows that the additional deletion of Fa2h does not obviously affect the phenotype of Cgt -/- mice. This suggests that HFA-GlcCer and HFA-sphingomyelin do not functionally compensate the loss of HFA-GalCer in Cgt -/- mice.
Generation of Fa2h-/-/Cgt-/- double deficient mice
In order to test the hypothesis that HFA-GlcCer partially compensates the loss of HFA-GalCer in Cgt-/- mice and thereby prevents a more severe phenotype, we generated Cgt-/- mice with an additional deficiency in Fa2h. As shown previously, young Fa2h-/- mice form structural and functional normal myelin  and did not show behavioral abnormalities that would indicate myelin deficiency. Older Fa2h-/-, however, developed a progressive axonal degeneration in peripheral nerves and brainstem, accompanied by myelin sheath degeneration . As shown before [3, 4], Cgt-/- mice had a strongly reduced life span, whereas Fa2h-/- mice did not show increased mortality (data not shown). Survival of Fa2h-/-/Cgt-/- double deficient mice was not significant different from Cgt-/- mice (around 50% survival at four weeks of age). There were no obvious behavioral differences between the two genotypes. However, because of the low amount of age-/weight- and gender-matched 4-week-old Cgt-/- and Fa2h-/-/Cgt-/- mice available, extensive behavioral testing could not be performed, and thus minor behavioral differences between Cgt-/- and Fa2h-/-/Cgt-/- mice cannot be ruled out. The following biochemical and morphological analyses were done with mice at 4 weeks of age.
GlcCer levels are reduced in CNS and PNS of Fa2h-/-/Cgt-/-mice when compared to Cgt-/- mice
To examine the possibility that GlcCer was replaced by gangliosides in myelin of Fa2h-/-/Cgt-/- mice, gangliosides were isolated and analyzed by TLC. Although the total amount of gangliosides in the myelin fraction of Fa2h-/-/Cgt-/- and Cgt-/- mice was increased compared to wild-type, the major myelin ganglioside GM1 was unchanged and only gangliosides normally found in neuronal membranes (GD1a, GD1b, GT1b) were increased (Figure 4B). Most likely these gangliosides are derived from neuronal membranes and possibly reflect a higher proportion of neuronal membrane contaminations in the Cgt-/- and Fa2h-/-/Cgt-/- mice, with their significant reduced amounts of compact myelin. In line with this, Saadat et al.  showed a similar relative composition of major gangliosides in myelin preparation from mice deficient in Ugcg in myelinating cells. We therefore believe that myelin ganglioside levels in Fa2h-/-/Cgt-/- mice were not increased compared to Cgt-/- mice or wild-type controls. In summary, we conclude that HFA-GlcCer present in Cgt-/- CNS myelin was replaced by only low amounts of NFA-GlcCer but larger amounts of NFA-sphingomyelin in Fa2h-/-/Cgt-/- mice. Taken together, these results indicate that myelin hexosylceramides were mainly replaced by sphingomyelin in the absence of Fa2h expression. It should be noted that the increase of sphingomyelin and the decrease of hexosylceramides were more pronounced in CNS myelin than in the PNS. This might indicate differences between oligodendrocytes and Schwann cells in the trafficking or metabolism of sphingolipids.
Myelination in Fa2h-/-/Cgt-/- mice as compared to Cgt-/- mice
Absence of GalCer and HFA-sphingolipids does not affect stability of CHAPS-insoluble membrane fractions
Comparable myelination in Fa2h-/-/Cgt-/- and Cgt-/- mice
No obvious structural differences between oligodendrocytes of Fa2h-/-/Cgt-/- and Cgt-/- were observed by the histological or electron microscopic analyses, however, a detailed structural analysis was not performed, and therefore we cannot exclude subtle structural changes in Fa2h-/-/Cgt-/- when compared to Cgt-/- mice (e.g. in the paranodal region).
Although HFA-sphingolipids appear to be dispensable for the formation of compact myelin , they are essential for long-term myelin maintenance and may also play a role in glia-dependent axonal support. In the absence of GalCer in Cgt-/- mice, compact myelin can be formed [3, 4], which is, however, unstable, also suggesting a role of GalCer in myelin maintenance. We hypothesized that HFA-sphingolipids may also play a more subtle role in early postnatal development, which could be detectable on a Cgt-/- background, where compact but less stable myelin is formed. However, we did not observe signs of a more severe phenotype in Fa2h-/-/Cgt-/- mice compared to Cgt-/- mice. At the behavioral level, Cgt-/- and Fa2h-/-/Cgt-/- mice were indistinguishable. Though there was a shift towards thicker myelin in Fa2h-/-/Cgt-/- compared to Cgt-/- mice, the g-ratios did not differ significantly between Cgt-/- and Fa2h-/-/Cgt-/- mice. Furthermore, myelin from Fa2h-/-/Cgt-/- and Cgt-/- mice was resistant towards extraction with CHAPS, as shown before for Fa2h-/- and wild-type mice .
Unexpectedly, HFA-GlcCer present in Cgt-/- mice was replaced by only low amounts of NFA-GlcCer in Fa2h-/-/Cgt-/- mice but higher levels of NFA-sphingomyelin. This suggests that the GlcCer concentration in myelin is not critical and furthermore that elevated GlcCer levels in Cgt-/- mice do not functionally compensate loss of GalCer. Accordingly, Saadat et al.  showed that deleting oligodendroglial glucosylceramide synthase (Ugcg) in Cgt-/- mice did not reinforce the myelin phenotype. This demonstrates that upregulation of (HFA)-GlcCer in Cgt-/- mice does not functionally compensate loss of GalCer in these mice. In Ugcg-deficient Cgt-/- mice, HFA-GlcCer was partially replaced by HFA-sphingomyelin . Our results demonstrate that HFA-sphingomyelin can be replaced by NFA-sphingomyelin without any obvious effect on the phenotype of Cgt-/- mice. Thus, the significant up-regulation of HFA-sphingomyelin in Cgt-/- mice is not a functional compensation.
The reason for the much lower NFA-GlcCer level in CNS myelin of Fa2h-/-/Cgt-/- mice compared to the HFA-GlcCer level in Cgt-/- mice is currently unknown. One possible explanation for the high HFA-GlcCer level and absence of HFA-gangliosides  in Cgt-/- mice could be the inability of the responsible glycosyltransferases to use HFA-GlcCer as a substrate. However, presence of a high amount of HFA-gangliosides in other tissues  and in tumor cells  argues against this. An alternative explanation could be differential sorting of HFA- and NFA-GlcCer, as shown for polarized epithelial cell lines , or reduced half-life of HFA-sphingolipids.
Although structural changes at the paranodes of Cgt-/- mice are clearly caused by sulfatide rather than GalCer deficiency [7, 25], myelin appear to be much more stable in young adult gal3st1-deficient mice, whereas myelin maintenance is already affected in young Cgt-/- mice , indicating additional function roles of HFA- and/or NFA-GalCer. Taken together, our results and those of Saadat et al.  strongly suggest that the upregulation of HFA-GlcCer and HFA-sphingomyelin in Cgt-/- mice does not functionally compensate the loss of HFA-GalCer in these mice. This, however, does not exclude the possibility that GalCer could be functionally replaced by GlcCer, if the latter would be present at higher concentrations than in Cgt-/- mice. The HFA-GlcCer concentration in Cgt-/- mice is clearly below the concentration of HFA-GalCer in wild-type but also in heterozygous Cgt+/- mice (which show a wild-type phenotype). There might be a relatively high threshold of hexosylceramide concentration in myelin to efficiently fulfill its role in myelin maintenance. This possibility could be tested using transgenic mice overexpressing Ugcg under control of an oligodendrocyte specific promoter, which to our knowledge are not available yet. Alternatively, the functional role of HFA- and/or NFA-GalCer may not be taken over by GlcCer or other glycolipids.
Our data indicate that compact myelin can be formed with non-hydroxylated sphingomyelin as the predominant sphingolipid, though myelin maintenance is impaired. While the specific role of GalCer in myelin maintenance remains mysterious, our results suggest that the presence of HFA-GlcCer and HFA-sphingomyelin in Cgt-/- mice does not functionally compensate the loss of HFA-GalCer.
Fa2h-/- mice have been described previously . Heterozygous Cgt+/- mice (kindly provided by Dr. Brian Popko, University of Chicago) were crossed with Fa2h-/- mice and double heterozygous Fa2h+/-/Cgt+/- mice were interbred or bred with Fa2h-/-/Cgt+/- mice to obtain mice of all possible nine genotypes. Genotyping was done using tail genomic DNA and the following oligonucleotides. Fa2h genotyping: 5'-GCTCTTCTTCAAGAGCCATCC-3', 5'-GTGCTGTACCTCAGCTGGTC-3'. 5'-ATTCGCAGCGCATCGCCTTCTATC-3', PCR products: 1045 bp for wild-type and 685 bp for the targeted allele; Cgt genotyping: 5'-TTACCAAGGAGTTCAGCAAACC-3', 5'-CCTCTCAGAAGGCAGAGACATTG-3', 5'-TCTGCACGAGACTAGTGAGACG-3', PCR products: 684 bp for wild-type and 820 bp for the targeted allele. All animal experiments followed internationally recognized guidelines and were approved by the Landesamt für Natur, Umwelt und Verbraucherschutz, Nordrhein-Westfalen, Germany.
Lipid extraction and thin layer chromatography
Total lipid extracts were prepared from brains, sciatic nerves, or purified myelin (from 4-week-old animals) according to Bligh and Dyer . In some experiments, phosphoglycerolipids were removed by mild alkaline hydrolysis as described . In order to isolate gangliosides from purified myelin, lipids were extracted as described by Folch et al  and the ganglioside containing upper phase was desalted by reversed-phase chromatography using RP-18 columns (Merck, Darmstadt, Germany). Lipids were separated by thin layer chromatography (TLC) in one of the following solvent systems: (1) chloroform/methanol/water (65/25/4) for hexosylceramides and sphingomyelin, (2) chloroform/methanol/acetic acid (190/9/1) for ceramides, and (3) chloroform/methanol/0.22% CaCl2 (60/35/4) to separate gangliosides. HPTLC silica gel 60 plates (Merck) were used for all experiments. To visualize lipids, HPTLC plates were sprayed with cupric sulfate in aqueous phosphoric acid  followed by charring at 180°C for 5 min. Lipids were quantified by densitometry and the GalCer and GlcCer levels were normalized to cholesterol. Data are shown as the mean ± SD and were tested for statistically significant differences by ANOVA with post hoc Fisher's least significant difference (LSD) test using the program STATISTICA.
Isolation of myelin
Compact myelin was isolated by sucrose gradient centrifugation as described by Norton and Poduslo , with minor modifications. Brains were homogenized in water using an Ultra-Turrax tissue homogenizer (IKA-Werke, Staufen, Germany). Aliquots of the homogenates were used for lipid extraction. The residual homogenates were adjusted to 10.5% (w/v) sucrose in 5 mM Tris-HCl (pH 7.4) and overlaid onto 10 ml of 30% (w/v) sucrose in 5 mM Tris-HCl (pH 7.4). After centrifugation (68,000×g, 50 min, 4°C) the enriched myelin fraction was recovered from the 10.5%/30% interphase, resuspended in 5 mM Tris-HCl (pH 7.4) and centrifuged at 68,000×g for 10 min. The resulting pellet was resuspended in 5 mM Tris-HCl (pH 7.4), centrifuged again, and the myelin was further purified by a second sucrose gradient centrifugation, followed by two washing steps in 5 mM Tris-HCl (pH 7.4). The final myelin pellet was resuspended in a small volume of water, lyophilized and stored at -80°C.
Analysis of CHAPS insoluble membrane fractions
CHAPS insoluble membrane fractions (CIMF) of purified myelin were prepared by optiprep density gradient centrifugation of myelin samples treated with 20 mM CHAPS at 37°C, as described previously [15, 21]. Six fractions of 350 μl each were removed from the top of the gradient and lipids were isolated from each fraction according to Bligh and Dyer , and analyzed by TLC as described above.
MALDI-TOF mass spectrometry
MALDI-TOF MS of hexosylceramides was done as described .
Brain samples were homogenized in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl (TBS), containing 5 mM EDTA and 1 mM PMSF, using an Ultra-Turrax tissue homogenizer (IKA-Werke, Staufen, Germany). Homogenates were centrifuged at 1,000×g for 5 min and the supernatant was mixed with SDS-PAGE sample buffer containing 2-mercaptoethanol. Proteins were separated in 12.5%-polyacrylamide gels and transferred to nitrocellulose membranes by semi-dry blotting. Membranes were stained with rabbit anti-myelin basic protein (MBP; dilution 1:10,000; Millipore, Schwalbach, Germany) and mouse anti-alpha-tubulin (Developmental Studies Hybridoma Bank, University of Iowa). Bound secondary antibodies were detected by enhanced chemiluminescence as described . Protein concentrations were determined with the Bio-Rad DC protein assay (Bio-Rad Laboratories, München, Germany) using bovine serum albumin as standard.
Axon caliber and myelin thickness were measured on toluidine-stained semithin sections of the cervical spinal cord of 4-week-old mice. Axonal caliber was determined by the diameter of a circle of area equivalent to each axon. The g-ratio was determined by dividing the diameter of the axon by the diameter of the fiber (axon with myelin). Quantification of myelinated axons was performed with a semi-automatic program on the basis of AnalySIS using a light microscope (100× objective, BX60, Olympus). All morphometric measurements were conducted in a blinded manner using coded sections. Ultrathin sections (50 nm) were photomicrographed with an EM10 electron microscope (Zeiss, Germany) at a magnification of 16.000×.
This work was supported by the Deutsche Forschungsgemeinschaft through SFB645 of the University of Bonn. The authors thank Dr. Brain Popko for providing the Cgt-/- mouse line and Dr. Andreas Ratzka for help with preparing the final version of the manuscript.
- Norton W, Cammer W: Isolation and characterization of myelin. Myelin. Edited by: Morell P. 1984, New York: Plenum Press, 147-180.View ArticleGoogle Scholar
- Eckhardt M: The role and metabolism of sulfatide in the nervous system. Mol. Neurobiol. 2008, 37: 93-103. 10.1007/s12035-008-8022-3.View ArticlePubMedGoogle Scholar
- Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Suzuki K, Popko B: Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell. 1996, 86: 209-219. 10.1016/S0092-8674(00)80093-8.View ArticlePubMedGoogle Scholar
- Bosio A, Binczek E, Stoffel W: Functional breakdown of the lipid bilayer of the myelin membrane in central and peripheral nervous system by disrupted galactocerebroside synthesis. Proc. Natl. Acad. Sci. U. S. A. 1996, 93: 13280-13285. 10.1073/pnas.93.23.13280.PubMed CentralView ArticlePubMedGoogle Scholar
- Dupree JL, Coetzee T, Blight A, Suzuki K, Popko B: Myelin galactolipids are essential for proper node of Ranvier formation in the CNS. J. Neurosci. 1998, 18: 1642-1649.PubMedGoogle Scholar
- Marcus J, Popko B: Galactolipids are molecular determinants of myelin development and axo-glial organization. Biochim. Biophys. Acta. 2002, 1573: 406-413.View ArticlePubMedGoogle Scholar
- Honke K, Hirahara Y, Dupree J, Suzuki K, Popko B, Fukushima K, Fukushima J, Nagasawa T, Yoshida N, Wada Y: Paranodal junction formation and spermatogenesis require sulfoglycolipids. Proc. Natl. Acad. Sci. U. S. A. 2002, 99: 4227-4232. 10.1073/pnas.032068299.PubMed CentralView ArticlePubMedGoogle Scholar
- Marcus J, Honigbaum S, Shroff S, Honke K, Rosenbluth J, Dupree JL: Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia. 2006, 53: 372-381. 10.1002/glia.20292.View ArticlePubMedGoogle Scholar
- Suzuki K, Vanier MT, Coetzee T, Popko B: Drastically abnormal gluco- and galactosylceramide composition does not affect ganglioside metabolism in the brain of mice deficient in galactosylceramide synthase. Neurochem. Res. 1999, 24: 471-474. 10.1023/A:1022571410445.View ArticlePubMedGoogle Scholar
- Coetzee T, Suzuki K, Popko B: New perspectives on the function of myelin galactolipids. Trends Neurosci. 1998, 21: 126-130. 10.1016/S0166-2236(97)01178-8.View ArticlePubMedGoogle Scholar
- Alderson NL, Rembiesa BM, Walla MD, Bielawska A, Bielawski J, Hama H: The human FA2H gene encodes a fatty acid 2-hydroxylase. J. Biol. Chem. 2004, 279: 48562-48568. 10.1074/jbc.M406649200.View ArticlePubMedGoogle Scholar
- Alderson NL, Maldonado EN, Kern MJ, Bhat NR, Hama H: FA2H-dependent fatty acid 2-hydroxylation in postnatal mouse brain. J. Lipid Res. 2006, 47: 2772-2780. 10.1194/jlr.M600362-JLR200.View ArticlePubMedGoogle Scholar
- Eckhardt M, Yaghootfam A, Fewou SN, Zoller I, Gieselmann V: A mammalian fatty acid hydroxylase responsible for the formation of alpha-hydroxylated galactosylceramide in myelin. Biochem. J. 2005, 388: 245-254. 10.1042/BJ20041451.PubMed CentralView ArticlePubMedGoogle Scholar
- Maldonado EN, Alderson NL, Monje PV, Wood PM, Hama H: FA2H is responsible for the formation of 2-hydroxy galactolipids in peripheral nervous system myelin. J. Lipid Res. 2008, 49: 153-161. 10.1194/jlr.M700400-JLR200.PubMed CentralView ArticlePubMedGoogle Scholar
- Zöller I, Meixner M, Hartmann D, Büssow H, Meyer R, Gieselmann V, Eckhardt M: Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J. Neurosci. 2008, 28: 9741-9754.View ArticlePubMedGoogle Scholar
- Edvardson S, Hama H, Shaag A, Gomori JM, Berger I, Soffer D, Korman SH, Taustein I, Saada A, Elpeleg O: Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am. J. Hum. Genet. 2008, 83: 643-648. 10.1016/j.ajhg.2008.10.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Dick KJ, Eckhardt M, Paisan-Ruiz C, Alshehhi AA, Proukakis C, Sibtain NA, Maier H, Sharifi R, Patton MA, Bashir W, Koul R, Raeburn S, Gieselmann V, Houlden H, Crosby AH: Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum. Mutat. 2010, 31: E1251-E1260. 10.1002/humu.21205.View ArticlePubMedGoogle Scholar
- Bosio A, Binczek E, Haupt WF, Stoffel W: Composition and biophysical properties of myelin lipid define the neurological defects in galactocerebroside- and sulfatide-deficient mice. J. Neurochem. 1998, 70: 308-315. 10.1046/j.1471-4159.1998.70010308.x.View ArticlePubMedGoogle Scholar
- Saadat L, Dupree JL, Kilkus J, Han X, Traka M, Proia RL, Dawson G, Popko B: Absence of oligodendroglial glucosylceramide synthesis does not result in CNS myelin abnormalities or alter the dysmyelinating phenotype of CGT-deficient mice. Glia. 2010, 58: 391-398. 10.1002/glia.20930.PubMed CentralView ArticlePubMedGoogle Scholar
- Zöller I, Büssow H, Gieselmann V, Eckhardt M: Oligodendrocyte-specific ceramide galactosyltransferase (CGT) expression phenotypically rescues CGT-deficient mice and demonstrates that CGT activity does not limit brain galactosylceramide level. Glia. 2005, 52: 190-198.View ArticlePubMedGoogle Scholar
- Simons M, Kramer EM, Thiele C, Stoffel W, Trotter J: Assembly of myelin by association of proteolipid protein with cholesterol- and galactosylceramide-rich membrane domains. J. Cell Biol. 2000, 151: 143-154. 10.1083/jcb.151.1.143.PubMed CentralView ArticlePubMedGoogle Scholar
- Hama H: Fatty acid 2-hydroxylation in mammalian sphingolipid biology. Biochim. Biophys. Acta. 2010, 1801: 405-414.PubMed CentralView ArticlePubMedGoogle Scholar
- Ladisch S, Sweeley CC, Becker H, Gage D: Aberrant fatty acyl alpha-hydroxylation in human neuroblastoma tumor gangliosides. J. Biol. Chem. 1989, 264: 12097-12105.PubMedGoogle Scholar
- van der Bijl P, Lopes-Cardozo M, van Meer G: Sorting of newly synthesized galactosphingolipids to the two surface domains of epithelial cells. J. Cell Biol. 1996, 132: 813-821. 10.1083/jcb.132.5.813.View ArticlePubMedGoogle Scholar
- Ishibashi T, Dupree JL, Ikenaka K, Hirahara Y, Honke K, Peles E, Popko B, Suzuki K, Nishino H, Baba H: A myelin galactolipid, sulfatide, is essential for maintenance of ion channels on myelinated axon but not essential for initial cluster formation. J. Neurosci. 2002, 22: 6507-6514.PubMedGoogle Scholar
- Bligh EG, Dyer WJ: A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37: 911-917.View ArticlePubMedGoogle Scholar
- van Echten-Deckert G: Sphingolipid extraction and analysis by thin-layer chromatography. Methods Enzymol. 2000, 312: 64-79. full_text.View ArticlePubMedGoogle Scholar
- Folch J, Lees M, Sloane Stanley GH: A simple method for the isolation and purification of total lipides from animal tissues. J. Biol. Chem. 1957, 226: 497-509.PubMedGoogle Scholar
- Norton WT, Poduslo SE: Myelination in rat brain: method of myelin isolation. J. Neurochem. 1973, 21: 749-757. 10.1111/j.1471-4159.1973.tb07519.x.View ArticlePubMedGoogle Scholar
- Eckhardt M, Barth H, Blöcker D, Aktories K: Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. J. Biol. Chem. 2000, 275: 2328-2334. 10.1074/jbc.275.4.2328.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.